<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109288</article-id><article-id pub-id-type="publisher-id">ACM-37549</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_70548997.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  TGF-β和PD-L1在膀胱癌浸润发展中的作用
  The Role of TGF-β and PD-L1 in the Invasion and Development of Bladder Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>灿</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>姜南</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>嘉乐</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>欧</surname><given-names>阳骏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>苏州大学，江苏 苏州</addr-line></aff><aff id="aff2"><addr-line>苏州大学附属第一医院泌尿外科，江苏 苏州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>1917</fpage><lpage>1925</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    膀胱癌是泌尿系统第二大常见肿瘤，其发病率和死亡率呈逐年上升趋势。近年来有多项研究发现转化生长因子β (transforming growth factor-β, TGF-β)和程序性死亡配体1 (Programmed death ligand 1, PD-L1)对膀胱癌浸润发展起重要作用，但其机制仍缺乏综合性论述。PD-L1/PD-1信号通路中分子异常表达已成为抗肿瘤靶向治疗的研究热点，而对TGF-β分子水平异常表达以及其与PD-L1/PD-1信号通路的相互作用探索较少，对TGF-β和PD-L1/PD-1信号通路的阐释有助于膀胱癌的靶向联合免疫治疗。本文分别简述了TGF-β和PD-L1单独作用以及共同作用对肿瘤微环境免疫抑制的影响。创新性地提出TGF-β和PD-L1/PD-1信号通路可通过以调节性T细胞(regulatory T cell, Treg)为桥梁的相互作用发挥联合免疫抑制作用，并强调了两者上游调控分子机制的重要性。
    Bladder cancer is the second most common tumor in the urinary system. Its incidence rate and mortality rate are increasing year by year. In recent years, many studies have found that transforming growth factor-β (TGF-β) and programmed death ligand 1 (PD-L1) play an important role in the invasion and development of bladder cancer, but the mechanism is still lack of comprehensive discussion. The abnormal expression of molecules in PD-L1/PD-1 signaling pathway has become a research hotspot of anti-tumor targeted therapy. However, there are few researches on the abnormal expression of TGF-β at molecular level and its interaction with PD-L1/PD-1 signaling pathway. The interpretation of TGF-β and PD-L1/PD-1 signaling pathway is helpful for targeted combined immunotherapy of bladder cancer. In this paper, the effects of TGF-β and PD-L1 on tumor microenvironment immunosuppression were reviewed. It is innovatively proposed that TGF-β and PD-L1/PD-1 signaling pathways can play a joint immunosuppressive role through the interaction of regulatory T cells (Treg) as a bridge, and the importance of upstream regulatory molecular mechanism of both is emphasized. 
  
 
</p></abstract><kwd-group><kwd>膀胱癌，转化生长因子β，程序性死亡配体-1，免疫抑制，免疫治疗, Bladder Cancer</kwd><kwd> Transforming Growth Factor-β</kwd><kwd> Programmed Death Ligand-1</kwd><kwd> Immunosuppression</kwd><kwd> Immunotherapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. 引言</title><p>膀胱癌(Bladder cancer, BCa)是泌尿系统中第二大常见的肿瘤，在我国的发病率达到80.5/10万 [<xref ref-type="bibr" rid="hanspub.37549-ref1">1</xref>]。膀胱癌按照肿瘤细胞侵袭的不同层次分为非肌层浸润性膀胱癌(Non-muscle invasive bladder cancer, NMIBC)和肌层浸润性膀胱癌(Muscle invasive bladder cancer, MIBC)。70%的病例出现在浅表阶段，但超过50%的NMIBC会出现复发，甚至有20%进展为肌层浸润型膀胱癌。目前，NMIBC的治疗主要以手术治疗和膀胱灌注化疗为主，MIBC的标准治疗方式是根治性全膀胱切除术和盆腔淋巴结清扫术后辅以顺铂化疗。然而治疗效果不尽如人意，多数患者因出现难以忍受的强烈化疗反应而放弃治疗。近30年来，探索浸润性膀胱癌的治疗方式停滞不前 [<xref ref-type="bibr" rid="hanspub.37549-ref2">2</xref>]。然而，随着转化生长因子β (Transforming growth factor-β, TGF-β)和程序性死亡配体1 (Programmed death ligand 1, PD-L1)通过抑制免疫细胞活化和浸润介导肿瘤免疫逃逸这一机制的发现，为晚期膀胱癌的治疗提供了新希望。本综述阐明TGF-β和PD-L1对膀胱癌浸润发展的作用，为膀胱癌的靶向免疫治疗提供理论基础。</p></sec><sec id="s2"><title>2. TGF-β相互作用组在膀胱癌发展中的作用</title><sec id="s2_1"><title>2.1. TGF-β分子结构及生物学功能</title><p>转化生长因子β (TGF-β)是一个具有多功能的多肽类细胞因子超家族，包括TGF-βs、激活素、抑制素、胚胎成形素(Nodal)、骨形成蛋白(BMPs)、抗苗勒管抑制素(AMH)和生长分化因子(GDFs)组成，其在所有多细胞中都有发现 [<xref ref-type="bibr" rid="hanspub.37549-ref3">3</xref>]。由于其受体也广泛表达于机体组织细胞，而TGF-β与其受体具有高度亲和力，因此TGF-β对多数细胞可发挥调节作用。TGF-β超家族C-末端包含9个半胱氨酸残基的生物活性区，靠分子间的二硫键形成二聚体，其中8个形成紧密的半胱氨酸结，而第9个对同源二聚化(homodimerization)至关重要 [<xref ref-type="bibr" rid="hanspub.37549-ref4">4</xref>]。脊椎动物基因组包含30多种TGF-β超家族的多效性配体，TGF-β超家族中的许多配体的异常表达和活性与发育缺陷与人类疾病有关 [<xref ref-type="bibr" rid="hanspub.37549-ref5">5</xref>]。TGF-β有5种异构体：TGF-β1-5，在哺乳动物中存在3种高度同源的亚型：TGF-β1、TGF-β2、TGF-β3，它们的表达水平因组织不同而不同，并且它们的功能也不同。</p><p>TGF-β参与了胚胎发育和成人组织中的动态平衡的一系列生物学过程。包括抑制细胞增殖、上皮–间充质转化的诱导、免疫抑制和炎症以及细胞外基质调节等功能。其最显著的特征是：肿瘤发生早期的抑瘤作用和肿瘤发生后期的促瘤作用。TGF-β强烈抑制多种细胞增殖，如上皮细胞、内皮细胞、造血细胞、免疫细胞等。在肿瘤发生早期阶段，TGF-β激活细胞周期蛋白依赖性激酶抑制剂CDKN1A和CDKN2A (分别编码p21CIP1和P12INK4b)的转录，介导细胞周期阻滞于G1期，从而抑制肿瘤细胞增殖 [<xref ref-type="bibr" rid="hanspub.37549-ref6">6</xref>]。但在肿瘤发生后期，TGF-β信号转导通路介导差异基因表达，导致细胞对TGF-β的抑制信号无反应，肿瘤微环境中反馈性增加TGF-β分泌，TGF-β过表达，导致上皮–间充质转化(EMT)，引起上皮细胞表型和极性变化，同时促进肿瘤内血管生成，增强肿瘤细胞的运动性和侵袭性 [<xref ref-type="bibr" rid="hanspub.37549-ref7">7</xref>]；抑制免疫细胞活性，参与肿瘤细胞免疫逃逸。</p></sec><sec id="s2_2"><title>2.2. TGF-β介导EMT过程与膀胱癌的关系</title><p>TGF-β1在膀胱癌组织中特异性表达，作为TGF-β的亚型之一，其主要通过EMT途径调节细胞外基质的组成来参与膀胱癌的侵袭和转移过程 [<xref ref-type="bibr" rid="hanspub.37549-ref8">8</xref>]。上皮–间充质转化(Epithelial mesenchyme transformation, EMT)是一个多步骤过程，通过EMT途径，尿路上皮细胞将获得高侵袭性与运动鞋的间充质特性 [<xref ref-type="bibr" rid="hanspub.37549-ref9">9</xref>]。EMT典型特征是上皮标记物如E-钙黏蛋白(E-cadherin)和细胞角蛋白下调，间充质标记物如波形蛋白(vimentin)上调 [<xref ref-type="bibr" rid="hanspub.37549-ref10">10</xref>]。上皮细胞具有重要的屏障功能，这一功能是通过细胞间的粘附介质紧密连接实现的，而上皮细胞中最重要的粘附介质是钙黏蛋白(cadherin)。钙黏蛋白水平下调使屏障功能丧失，引起上皮细胞的形态学改变，增加细胞的运动能力，这与肿瘤的侵袭和转移密切相关，在膀胱癌的发展中起重要作用。第一批被鉴定的钙黏蛋白是E-cadherin、P-cadherin、N-cadherin [<xref ref-type="bibr" rid="hanspub.37549-ref11">11</xref>]。E-cadherin在上皮间的相互作用起最至关重要的作用，它介导相邻细胞间的紧密连接，并维持上皮细胞的表型和顶端极性。由于E-cadherin这些功能，它在抑制肿瘤侵袭性方面起关键作 [<xref ref-type="bibr" rid="hanspub.37549-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.37549-ref13">13</xref>]。钙黏蛋白转换(cadherin switch)是EMT过程中的一个关键性变化，在此过程中，E-cadherin的正常表达被P-cadherin和N-cadherin的异常表达所取代，从而导致E-cadherin (CDH1)水平下调，而它的下调可能有助于肿瘤进展的另一种方式，即释放β-连环蛋白(β-catenin，又CTNNB1)。CDH1的胞质结构域通过CTNNA1和CTNNB1锚定在肌动蛋白细胞的骨架上，为粘附连接提供机械稳定性 [<xref ref-type="bibr" rid="hanspub.37549-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.37549-ref15">15</xref>]。当CDH1下调时，CTNNB1被释放，并迁移到胞核激活WNT靶基因，导致EMT和更多的转移形成 [<xref ref-type="bibr" rid="hanspub.37549-ref16">16</xref>]。基于以上分析，CDH1和CTNNB1常被用来检测胚胎发育和肿瘤发展过程中的EMT进展。TGF-β1通过激活Smad3/4信号通路诱导锌指转录因子1 (Snail1)的强烈启动，而Snail1再激活ZEB-1/ZEB-2和Snail2，后两者共同抑制CDH1水平，进而导致EMT进展 [<xref ref-type="bibr" rid="hanspub.37549-ref17">17</xref>]。除此之外，TGF-β还可通过增强转录因子Snail/Ets-1的表达来调节基质金属蛋白(MMP-9)，促进肿瘤EMT [<xref ref-type="bibr" rid="hanspub.37549-ref18">18</xref>]。POK红系髓系成体因子(Pokemon)是POK家族转录抑制因子的成员，在细胞转化和恶性肿瘤中起着重要作用。Wei Li [<xref ref-type="bibr" rid="hanspub.37549-ref7">7</xref>] 等发现TGF-β1抑制代表膀胱癌细胞的T24细胞的增殖和迁移，Pokemon在膀胱细胞中高度表达，TGF-β1可能抑制Pokemon和CDH1的表达，Pokemon和CDH1的低表达导致了上皮细胞表型改变和根尖极性增加，这些细胞的改变引起EMT并最终导致膀胱癌的复发和转移。</p></sec><sec id="s2_3"><title>2.3. TGF-β在膀胱癌免疫抑制和炎症中的作用</title><p>TGF-β对免疫系统的大多数前体细胞有较强的生长抑制作用，是T细胞的有效抑制因子和B细胞的凋亡的诱导剂。Rosemary等 [<xref ref-type="bibr" rid="hanspub.37549-ref19">19</xref>]。发现敲除TGF-β1基因的小鼠出现出生后致死性炎症反应，表明该配体具有重要的免疫抑制作用。TGF-β受体在所有类型的免疫细胞上广泛表达。TGF-β阻碍树突状细胞的抗原提呈作用，使肿瘤细胞失去免疫应答；IL-2诱导产生NK细胞，在膀胱癌中，TGF-β的过量表达阻断IL-2的产生而导致NK细胞减少并同时破坏宿主CD8+细胞等介导的细胞毒作用，共同完成肿瘤细胞的免疫逃逸。研究显示树突状细胞和NK细胞在头颈鳞癌中存在功能性失活；此外，转录因子Foxp3的表达驱动的抑制性Treg细胞对于维持外周免疫耐受以及调节肿瘤免疫和感染至关重要；至于天然免疫系统的细胞，TGF-β通过Smad3途径对干扰素γ启动子的转录作用，直接抑制NK细胞介导的干扰素γ的产生。它还将巨噬细胞和中性粒细胞从I型表型(攻击和吞噬癌细胞)转变为II型表型(产生大量炎症分子)。这些分子会加重局部的疾病状态，导致实体肿瘤进展或炎症与纤维化；Th17细胞产生的IL-17能有效地介导中性粒细胞动员的兴奋过程，从而有效地介导了组织的炎症反应。相关研究报道，TGF-β可诱导Smad2与RORgt途径结合，促使CD4+T细胞向Th17细胞分化 [<xref ref-type="bibr" rid="hanspub.37549-ref20">20</xref>]。然而围绕这一话题仍存在巨大争议。还有些研究发现，过量表达的TGF-β下调主要组织相容性复合体(MHC)Ⅰ类和Ⅱ类分子的表达，并使激活杀伤细胞的淋巴因子失活，阻止免疫球蛋白的合成 [<xref ref-type="bibr" rid="hanspub.37549-ref21">21</xref>]。由此可见，TGF-β通过免疫抑制在肿瘤微环境中发挥了促癌作用。进一步的研究也显示抑制肿瘤微环境中的TGF-β，可以促进免疫细胞对肿瘤细胞的免疫反应，这一发现也奠定了以TGF-β为中心的免疫疗法的理论基础。</p></sec><sec id="s2_4"><title>2.4. TGF-β对膀胱癌转移的作用</title><p>膀胱癌的发展过程离不开血管的营养支持，并且膀胱癌内新生的血管有助于其转移。诱导新生血管由肿瘤细胞释放的血管内皮生长因子(VEGF、FGF等)来完成，而TGF-β在血管内皮生长因子起到旁分泌调节作用，刺激内皮细胞和毛细血管腔生成，TGF-β也在膀胱癌的转移中发挥着至关重要的作用。</p><p>在组织中，TGF-β结合蛋白与TGF-β结合，在胞外基质中储存，TGF-β的II型受体(II-R)被刺激后自动磷酸化与TGF-β结合，其蛋白激酶活性催化I-R磷酸化——磷酸化后的I-R继续磷酸化下游分子，使信号传到胞内并进一步磷酸化Smad2或3，之后再与Smad4结合形成复合物转入胞核内进行基因调控。该过程正常情况下可抑制肿瘤生长，然而在肿瘤发展阶段，信号通路的主要蛋白出现基因突变和缺失，引起该通路转导异常从而导致肿瘤的浸润转移，其中具有代表性的有miR-211。Chu等 [<xref ref-type="bibr" rid="hanspub.37549-ref22">22</xref>] 的研究表明，超过60％的转移性头颈部鳞状细胞癌组织表现出II-R表达下调，miR-211可能通过抑制II-R，破坏Smad3磷酸化和上调c-Myc表达而促进头颈部鳞状细胞癌。表明II-R的表达下降与和肿瘤的高度侵袭性、高度淋巴结转移率、预后不良呈正相关。在两个受体的启动子基因突变或者甲基化下，mRNA水平下降，进而两者同时下降；纯合子Smad4的基因缺失，导致Smad失去TGFβ分子的核转运功能，致使下游的靶基因不能启动，下游信号中断。Smad4蛋白的缺失或者失活在胰腺癌、结肠癌、头颈癌中均有相关表达 [<xref ref-type="bibr" rid="hanspub.37549-ref18">18</xref>]。</p></sec></sec><sec id="s3"><title>3. PD-L1在膀胱癌中的作用</title><sec id="s3_1"><title>3.1. PD-L1分子结构</title><p>程序性死亡因子1 (programmed death 1, PD-1)属于B7家族的一员，作为抑制性受体，表达于活化的T细胞、B细胞、NK细胞和巨噬细胞表面，它有两个配体：程序性死亡配体-1 (programmed death-ligand 1，PD-L1，又称B7H1或CD274)和程序性死亡配体-2 (programmed death-ligand 2, PD-L2)，虽然PD-L2和PD-1的亲和力相较于PD-L1高，但PD-L1的表达范围更广，所以目前的研究多集中在PD-L1方向上 [<xref ref-type="bibr" rid="hanspub.37549-ref23">23</xref>]。PD-L1是一种含有290个氨基酸的I型跨膜蛋白，由胞外区的IgV和IgC结构域、疏水性跨膜结构域、30个氨基酸片段和带电荷的胞内区组成，编码PD-L1的基因位于染色体9p24 [<xref ref-type="bibr" rid="hanspub.37549-ref24">24</xref>]。</p></sec><sec id="s3_2"><title>3.2. PD-L1在肿瘤中的免疫抑制作用</title><p>APC有两个信号通路可通过诱导CD8+T细胞向溶解细胞分化的途径来发挥对肿瘤细胞的免疫和清除。一种信号是MHC上呈现的来自肿瘤细胞的抗原肽与T细胞的相互作用；另一类是APC上的共刺激信号PD-1和PD-2，它们与T细胞上的CD28、CD152或者CTLA-4结合，许多情况下，宿主的免疫反应直接涉及这两个信号。然而，癌细胞可以逃脱宿主的免疫反应，这些逃避机制包括减少共刺激分子CD80和CD86、粘附分子或癌细胞上Fas配体的表达，下调MHC-I类分子的表达，以及抗原处理缺陷 [<xref ref-type="bibr" rid="hanspub.37549-ref25">25</xref>]。此外，近年来对PD-1的大量研究证明，PD-1在保护癌细胞免受细胞毒T细胞的攻击和抑制I型介导的细胞毒性起重要作用。其配体PD-L1作为一种抑制性免疫调节分子少量存在于正常细胞表面，当免疫系统过度激活时，免疫细胞表面的抑制性分子PD-1与正常细胞表面的PD-L1结合进而抑制免疫活性，避免过度激活的免疫系统杀伤自身正常细胞。但在肿瘤发生时，肿瘤微环境中常可发现高水平的PD-L1，它与T细胞表面的抑制性受体PD-1结合，形成一对负性共刺激分子，一方面促进T细胞凋亡，并抑制白细胞介素2 (interleukin-2, IL-2)、干扰素γ (interferon-γ, IFN-γ)等杀伤肿瘤的细胞因子，同时诱导T细胞分泌IL-10，抑制肿瘤免疫应答；另一方面减少T细胞活化所必需的第二信号，使其失能并导致免疫失活 [<xref ref-type="bibr" rid="hanspub.37549-ref26">26</xref>]。肿瘤微环境中大量表达的PD-L1让免疫细胞误以为肿瘤细胞是“友军”，让这种自身免疫保护变成肿瘤细胞的免疫逃逸。因此，PD-L1/PD-1信号转导在肿瘤免疫逃逸中起着至关重要的作用。</p><p>大量研究表明肿瘤细胞表达PD-L1抑制肿瘤免疫，如头颈部鳞状细胞癌、肺癌、乳腺癌、黑色素瘤和子宫内膜癌等。以乳腺癌为例，PD-L1在原代细胞上高表达，与雌激素、孕酮阴性表达状态和组织学类型有关，还与高增殖且表达Ki-67的肿瘤细胞、大肿瘤和预后不良相关 [<xref ref-type="bibr" rid="hanspub.37549-ref27">27</xref>]。此外，PD-L1在小鼠肿瘤细胞系(如肥大细胞系、黑色素瘤)中的转基因表达有助于它们逃避宿主T细胞，并显著增强在体内的侵袭性。相反，其他研究表明PD-L1与良好的疾病预后相关。原发性乳腺癌和肺癌组织中PD-L1的表达与TIL增加有关，TIL的增加与较长的无复发生存期相关；同样，PD-L1过表达的NSCLC患者的总生存期更长，这与患者年龄、分期和组织学无关。此外，与PD-L1阴性的转移性黑色素瘤相比，PD-L1阳性的转移性黑色素瘤的进展延迟 [<xref ref-type="bibr" rid="hanspub.37549-ref28">28</xref>]。在癌症中，PD-L1的表达是否会导致更好或更差的预后仍不清楚。PD-L2的机制仍未阐释清楚。但我们却已知肿瘤细胞可通过浸润的免疫细胞产生的干扰素-γ介导多种致癌信号途径刺激PD-L1的表达，如NF-kB、MAPK、mTOR、MEK/ERK/STAT1、PI3K和JAK/STAT等。例如，阻断MEK/ERK通路可以抑制Toll样受体配体干扰素-γ在骨髓瘤患者血浆中诱导PD-L1表达 [<xref ref-type="bibr" rid="hanspub.37549-ref29">29</xref>]。mTOR抑制剂雷帕霉素和AKT抑制剂MK-2206抑制PI3K信号转导导致PD-L1表达下降。这些发现表明PD-L1在肿瘤中表达的重要性，对肿瘤患者体内PD-L1的检测意义非凡。</p></sec><sec id="s3_3"><title>3.3. PD-L1与膀胱癌的关系</title><p>肿瘤浸润、转移是膀胱癌患者死亡的首要原因，肿瘤免疫逃逸是造成肿瘤浸润、转移的重要因素。Lin Z.等 [<xref ref-type="bibr" rid="hanspub.37549-ref30">30</xref>] 基于61篇文献资料的Meta分析提示PD-L1高表达与肿瘤侵袭性和不良预后呈正相关，且PD-L1在肿瘤中的表达率亚洲人高于白种人。近年研究已证实，PD-L1表达水平与膀胱肿瘤的T分期、肿瘤级别呈正相关，除此之外，Nakanishi等 [<xref ref-type="bibr" rid="hanspub.37549-ref31">31</xref>] 应用流式细胞测定13例尿路上皮癌标本还发现PD-L1表达水平在CD8+T细胞显著高于CD4+T细胞，说明CD8+T细胞在膀胱肿瘤免疫逃逸中发挥主要作用。CD8+T细胞通常活化后分化为细胞毒性T淋巴细胞(CTL)，CTL通过识别特异性抗原和Ⅰ类MHC分子来杀伤肿瘤细胞。然而，MHCⅠ类分子在低分化和转移性肿瘤中低表达甚至不表达，导致肿瘤细胞逃避CTL介导的肿瘤杀伤效应 [<xref ref-type="bibr" rid="hanspub.37549-ref32">32</xref>]。此外，抗原调变、抗原遮蔽等方式也是肿瘤细胞进一步逃避机体免疫细胞有效识别的方式 [<xref ref-type="bibr" rid="hanspub.37549-ref33">33</xref>]。上述机制的发现使PD-1/PD-L1抑制剂成为肿瘤免疫治疗的热点研究方向，第一个抗PD-L1单克隆抗体药物Atezolizumab在2016年5月被美国FDA获批用于转移性尿路上皮癌的治疗。尽管以PD-L1为靶点的免疫治疗取得了重大的进步，但仍需注意到PD-1/PD-L1抑制剂仅对部分PD-L1阳性的病人有效，前期临床试验表明其客观缓解率仅为40%~50%且对同一患者前期疗效显著后期疗效乏力 [<xref ref-type="bibr" rid="hanspub.37549-ref34">34</xref>]。</p></sec></sec><sec id="s4"><title>4. PD-L1与TGF-β对膀胱癌的共同作用</title><p>TGF-β和PD-L1可通过直接或间接作用以及通过与调节性T细胞(regulatory T cell, Treg)的相互作用介导肿瘤细胞免疫逃逸。肿瘤微环境中的免疫调节因子如IL-6、IL-10可上调抗原提呈细胞(APC)中的PD-L1，进而释放TGF-β等可溶性抑制性因子，TGF-β进一步以Smad2途径上调PD-L1基因转录和表达，又反过来上调APC中的PD-L1水平，两者通过这种直接的双向整性协同作用上调在肿瘤微环境的水平，并各自发挥作用达到抑制免疫细胞浸润和促肿瘤作用 [<xref ref-type="bibr" rid="hanspub.37549-ref35">35</xref>] [<xref ref-type="bibr" rid="hanspub.37549-ref36">36</xref>]。调节性T细胞是一类调节自身免疫反应性的T细胞亚群，TGF-β和PD-L1以Treg为“桥梁”在肿瘤微环境中持续性诱导抑制性Treg细胞的分化，三者协同抑制T细胞活化，导致肿瘤逃避免疫监视。在正常机体中中，Treg细胞主要表型CD4+CD25+Treg细胞特征性高表达转录因子Foxp3，Foxp3为CD4+CD25+T细胞分泌TGF-β和IL-10因子抑制免疫过度活化，从而避免自身免疫性疾病。但在膀胱肿瘤微环境中，高表达的PD-L1通过下调磷酸化Akt、mTOR、S6和ERK2以及上调PTEN等介导Foxp3+Treg细胞的异常发育。</p><p>在Treg细胞中，DNA去甲基化对Foxp3+转录必不可少，TGF-β同样对Treg细胞中Foxp3+的分化至关重要。Sun等 [<xref ref-type="bibr" rid="hanspub.37549-ref37">37</xref>] 发现uhrf1在TGF-β处理后被磷酸化，并被排除在细胞核之外，磷酸化的uhrf1发生蛋白酶体降解，DNA甲基化介导的Foxp3启动子区域的抑制被逆转，进而促Foxp3+转录。但TGF-β本身对免疫细胞的抑制不依赖于Foxp3+，TGF-β作为祖转化生长因子成员，可能是一种辅助调节T细胞免疫活性的内在机制，哺乳动物获得Foxp3+位点上的TGF-β调控元件后，进一步参与诱导外周Treg细胞分化 [<xref ref-type="bibr" rid="hanspub.37549-ref38">38</xref>]。Cohen等人 [<xref ref-type="bibr" rid="hanspub.37549-ref39">39</xref>] 发现TGF-β在幼稚细胞刺激糖皮质激素可诱导亮氨酸拉链蛋白，而此蛋白的一个特殊功能就是上调PD-L1的表达，表明TGF-β可间接促进PD-L1表达。实验表明，在极少量的TGF-β的刺激下，野生型APC即可显著诱导幼稚CD4+T细胞转变为Foxp3+Treg细胞，相反在相同TGF-β浓度下，PD-L1阴性的幼稚细胞转化为Foxp3+Treg细胞的数量显著减少 [<xref ref-type="bibr" rid="hanspub.37549-ref40">40</xref>]。由上可知，Foxp3+Treg细胞通过产生TGF-β和IL-10天然发挥负性免疫调控，而PD-L1的高表达导致Treg细胞中Foxp3的异常高表达，同时当极少量TGF-β存在时，PD-L1也能够异常增加Foxp3+Treg细胞数量。因此，TGF-β和PD-L1除了能够直接相互影响外，TGF-β还可以间接促PD-L1高表达，并且两者与Foxp3+Treg形成了互利共生的免疫抑制生态模式，在介导肿瘤免疫豁免中发挥相辅相成的作用。</p></sec><sec id="s5"><title>5. 小结</title><p>综上，TGF-β和PD-L1是膀胱肿瘤微环境中的重要免疫抑制性分子。TGF-β通过EMT途径、抑制免疫细胞增殖分化和促肿瘤内血管生成等方式参与膀胱癌的浸润和发展；PD-L1通过PD-1结合形成负性共刺激分子导致膀胱癌细胞逃避免疫监视。TGF-β和PD-L1的高表达水平在膀胱肿瘤免疫逃逸中至关重要，TGF-β和PD-L1既可以单独影响又可以相互作用共同影响肿瘤微环境中免疫抑制作用，因此探索降低肿瘤微环境中TGF-β和PD-L1水平的联合药物具有非常重要的意义。此外，若两者上游调控分子机制得以发现证实，不妨作为膀胱癌免疫治疗的新思路。</p></sec><sec id="s6"><title>6. 研究展望</title><p>肿瘤微环境对肿瘤的浸润发展转移具有重要作用，但其机制仍需要进一步研究。近些年，膀胱癌的发病率逐年递增，联合免疫治疗成为膀胱癌免疫疗法的趋势，有效地应用于防止肿瘤复发和进展以及晚期膀胱癌患者的治疗。目前针对膀胱癌的PD-1/PD-L1研究比较完善，相关免疫药物也已上市，但其仍存在客观缓解率(ORR)较低以及不适合PD-L1阴性患者等问题，而抗TGF-β抗体可改善这种情况，TGF-β和PD-L1双靶向抗体治疗仍需大量证据支持，相信随着研究深入，联合靶向药物的应用将会逐步规范并实现。</p></sec><sec id="s7"><title>基金项目</title><p>项目名称：PD-1/TGFβ 双靶向特异性抗体治疗膀胱癌临床前实验研究。项目编号：SLJ201906。负责人：欧阳骏，苏州大学附属第一人民医院泌尿外科。</p></sec><sec id="s8"><title>文章引用</title><p>胡 灿,徐姜南,孙嘉乐,欧阳骏. TGF-β和PD-L1在膀胱癌浸润发展中的作用 The Role of TGF-β and PD-L1 in the Invasion and Development of Bladder Cancer[J]. 临床医学进展, 2020, 10(09): 1917-1925. https://doi.org/10.12677/ACM.2020.109288</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37549-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Chen,W.Q., Zheng, R.S., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. &lt;br&gt;https://doi.org/10.3322/caac.21338</mixed-citation></ref><ref id="hanspub.37549-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lobo, N., Mount, C., Omar, K., Nair, R., Thurairaja, R. and Khan, M.S. (2017) Landmarks in the Treatment of Muscle-Invasive Bladder Cancer. Nature Reviews Urology, 14, 565-574.</mixed-citation></ref><ref id="hanspub.37549-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Schmierer, B. and Hill, C.S. (2007) Tgfβ-SMAD Signal Transduction: Molecular Specificity and Functional Flexibility. Nature Reviews Molecular Cell Biology, 8, 970-982. &lt;br&gt;https://doi.org/10.1038/nrm2297</mixed-citation></ref><ref id="hanspub.37549-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Morikawa, M., Derynck, R. and Miyazono, K. (2016) TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. Cold Spring Harbor Perspectives in Biology, 8, A021873.  
&lt;br&gt;https://doi.org/10.1101/cshperspect.a021873</mixed-citation></ref><ref id="hanspub.37549-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Harradine, K.A. and Akhurst, R.J. (20096) Mutations of Tgfβ Signaling Molecules in Human Disease. Annals of Medicine, 38, 403-414. &lt;br&gt;https://doi.org/10.1080/07853890600919911</mixed-citation></ref><ref id="hanspub.37549-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Gomis, R.R., Alarcón, C., He, W., et al. (2006) A Foxo-Smad Synexpression Group in Human Keratinocytes. Proc Proceedings of the National Academy of Sciences of the United States of America, 103, 12747-12752.  
&lt;br&gt;https://doi.org/10.1073/pnas.0605333103</mixed-citation></ref><ref id="hanspub.37549-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Li, W., Kidiyoor, A., Hu, Y.Y., et al. (2015) Evaluation of Transforming Growth Factor-β1 Suppress Pokemon or Epithelial-Mesenchymal Transition Expression in Human Bladder Cancer Cells. Tumor Biology, 36, 1155-1162.  
&lt;br&gt;https://doi.org/10.1007/s13277-014-2625-2</mixed-citation></ref><ref id="hanspub.37549-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Eder, I.E., Stenzl, A., Hobisch, A., Cronauer, M.V., Bartsch, G. and Klocker, H. (1996) Transforming Growth Factors-Beta 1 and Beta 2 in Serum and Urine from Patients with Bladder Carcinoma. Journal of Urology, 156, 953-957. 
&lt;br&gt;https://doi.org/10.1016/S0022-5347(01)65670-2</mixed-citation></ref><ref id="hanspub.37549-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Smith, A.L., Iwanaga, R., Drasin, D.J., et al. (2012) The miR-106b-25 Cluster Targets Smad7, Activates TGF-β Signaling, and Induces EMT and Tumor Initiating Cell Characteristics Downstream of Six1 in Human Breast Cancer. Oncogene, 31, 5162-5171. &lt;br&gt;https://doi.org/10.1038/onc.2012.11</mixed-citation></ref><ref id="hanspub.37549-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Waerner, T., Alacakaptan, M., Tamir, I., et al. (2006) ILEI: A Cytokine Essential for EMT, Tumor Formation, and Late Events in Metastasis in Epithelial Cells. Cancer Cell, 10, 227-239. &lt;br&gt;https://doi.org/10.1016/j.ccr.2006.07.020</mixed-citation></ref><ref id="hanspub.37549-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nollet, F., Kools, P. and Van Roy, F. (2000) Phylogenetic Analysis of the Cadherin Superfamily Allows Identification of Six Major Subfamilies besides Several Solitary Members. Journal of Molecular Biology, 299, 551-572.  
&lt;br&gt;https://doi.org/10.1006/jmbi.2000.3777</mixed-citation></ref><ref id="hanspub.37549-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chaw, S.Y., Abdul Majeed, A., Dalley, A.J., Chan, A., Stein, S. and Farah, C.S. (2012) Epithelial to Mesenchymal Transition (EMT) Biomarkers—E-Cadherin, Beta-Catenin, APC and Vimentin—In Oral Squamous Cell Carcinogenesis and Transformation. Oral Oncology, 48, 997-1006. &lt;br&gt;https://doi.org/10.1016/j.oraloncology.2012.05.011</mixed-citation></ref><ref id="hanspub.37549-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Froeling, F.E., Mirza, T.A., Feakins, R.M., et al. (2009) Organotypic Culture Model of Pancreatic Cancer Demonstrates That Stromal Cells Modulate E-Cadherin, β-Catenin, and Ezrin Expression in Tumor Cells. The American Journal of Pathology, 175, 636-648. &lt;br&gt;https://doi.org/10.2353/ajpath.2009.090131</mixed-citation></ref><ref id="hanspub.37549-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">De Wever, O., Pauwels, P., De Craene, B., et al. (2008) Molecular and Pathological Signatures of Epithelial-Mesenchymal Transitions at the Cancer Invasion Front. Histochemistry and Cell Biology, 130, 481-494.  
&lt;br&gt;https://doi.org/10.1007/s00418-008-0464-1</mixed-citation></ref><ref id="hanspub.37549-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yilmaz, M. and Christofori, G. (2009) EMT, the Cytoskeleton, and Cancer Cell Invasion. Cancer and Metastasis Reviews, 28, 15-33. &lt;br&gt;https://doi.org/10.1007/s10555-008-9169-0</mixed-citation></ref><ref id="hanspub.37549-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Van Der Horst, G., Bos, L. and Van Der Pluijm, G. (2012) Epithelial Plasticity, Cancer Stem Cells, and the Tumor-Supportive Stroma in Bladder Carcinoma. Molecular Cancer Research, 10, 995-1009.  
&lt;br&gt;https://doi.org/10.1158/1541-7786.MCR-12-0274</mixed-citation></ref><ref id="hanspub.37549-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Thuault, S., Tan, E.J., Peinado, H., Cano, A., Heldin, C.H. and Moustakas, A. (2008) HMGA2 and Smads Co-Regulate SNAIL1 Expression during Induction of Epithelial-To-Mesenchymal Transition. The Journal of Biological Chemistry, 283, 33437-33446. &lt;br&gt;https://doi.org/10.1074/jbc.M802016200</mixed-citation></ref><ref id="hanspub.37549-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">闫鹏, 达林泰, 德乐黑巴特尔. TGF-β/Smad信号通路在恶性肿瘤作用及基理研究进展[J]. 内蒙古医科大学学报, 2018, 40(5): 541-544.</mixed-citation></ref><ref id="hanspub.37549-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Shimizu, J., Izumi, T., Arimitsu, N., et al. (2012) Skewed TGFβ/Smad Signalling Pathway in T Cells in Patients with Behçet’s Disease. Clinical and Experimental Rheumatology, 30, S35-S39.</mixed-citation></ref><ref id="hanspub.37549-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.J., Chang, Y.L., Lai, W.L., et al. (2011) Increased Prevalence of Interleukin-17-Producing CD4+ Tumor Infiltrating Lymphocytes in Human Oral Squamous Cell Carcinoma. Head &amp; Neck, 33, 1301-1308. 
 &lt;br&gt;https://doi.org/10.1002/hed.21607</mixed-citation></ref><ref id="hanspub.37549-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Letterio, J.J. and Roberts, A.B. (1998) Regulation of Immune Responses by TGF-β. Annual Review of Immunology, 16, 137-161. &lt;br&gt;https://doi.org/10.1146/annurev.immunol.16.1.137</mixed-citation></ref><ref id="hanspub.37549-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Chu, T.H., Yang, C.C., Liu, C.J., Lui, M.T., Lin, S.C. and Chang, K.W. (2013) MiR-211 Promotes the Progression of Head and Neck Carcinomas by Targeting TGFβRII. Cancer Letters, 337, 115-124.  
&lt;br&gt;https://doi.org/10.1016/j.canlet.2013.05.032</mixed-citation></ref><ref id="hanspub.37549-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Topalian, S.L., Taube, J.M., Anders, R.A. and Pardoll, D.M. (2016) Mechanism-Driven Biomarkers to Guide Immune Checkpoint Blockade in Cancer Therapy. Nature Reviews Cancer, 16, 275-287. &lt;br&gt;https://doi.org/10.1038/nrc.2016.36</mixed-citation></ref><ref id="hanspub.37549-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Sharpe, A.H., Wherry, E.J., Ahmed, R. and Freeman, G.J. (2007) The Function of Programmed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection. Nature Immunology, 8, 239-245. &lt;br&gt;https://doi.org/10.1038/ni1443</mixed-citation></ref><ref id="hanspub.37549-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F. and Stern, P.L. (1993) Natural History of HLA Expression during Tumour Development. Immunology Today, 14, 491-499.  
&lt;br&gt;https://doi.org/10.1016/0167-5699(93)90264-L</mixed-citation></ref><ref id="hanspub.37549-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Muenst, S., Schaerli, A.R., Gao, F., et al. (2014) Expression of Programmed Death Ligand 1 (PD-L1) Is Associated with Poor Prognosis in Human Breast Cancer. Breast Cancer Research and Treatment, 146, 15-24.  
&lt;br&gt;https://doi.org/10.1007/s10549-014-2988-5</mixed-citation></ref><ref id="hanspub.37549-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Taube, J.M., Anders, R.A., Young, G.D., et al. (2012) Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine, 4, 127ra37. &lt;br&gt;https://doi.org/10.1126/scitranslmed.3003689</mixed-citation></ref><ref id="hanspub.37549-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Liu, J.Z., Hamrouni, A., Wolowiec, D., et al. (2007) Plasma Cells from Multiple Myeloma Patients Express B7-H1 (PD-L1) and Increase Expression after Stimulation with IFN-γ and TLR Ligands via a Myd88-, TRAF6-, and MEK-Dependent Pathway. Blood, 110, 296-304. &lt;br&gt;https://doi.org/10.1182/blood-2006-10-051482</mixed-citation></ref><ref id="hanspub.37549-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Bellmunt, J., Powles, T. and Vogelzang, N.J. (2017) A Review on the Evolution of PD-1/PD-L1 Immunotherapy for Bladder Cancer: the Future Is Now. Cancer Treatment Reviews, 54, 58-67.  
&lt;br&gt;https://doi.org/10.1016/j.ctrv.2017.01.007</mixed-citation></ref><ref id="hanspub.37549-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Lin, Z., Xu, Y., Zhang, Y., et al. (2016) The Prevalence and Clinicopathological Features of Programmed Death-Ligand 1 (PD-L1) Expression: A Pooled Analysis of Literatures. Oncotarget, 7, 15033-15046.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.7590</mixed-citation></ref><ref id="hanspub.37549-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K. and Ueda, S. (2007) Overexpression of B7-H1 (PD-L1) Significantly Associates with Tumor Grade and Postoperative Prognosis in Human Urothelial Cancers. Cancer Immunology, Immunotherapy, 56, 1173-1182. &lt;br&gt;https://doi.org/10.1007/s00262-006-0266-z</mixed-citation></ref><ref id="hanspub.37549-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Khong, H.T., Wang, Q.J. and Rosenberg, S.A. (2004) Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes from a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression. Journal of Immunotherapy, 27, 184-190. &lt;br&gt;https://doi.org/10.1097/00002371-200405000-00002</mixed-citation></ref><ref id="hanspub.37549-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Rosenberg, S.A. (2001) Progress in Human Tumour Immunology and Immunotherapy. Nature, 411, 380-384.  
&lt;br&gt;https://doi.org/10.1038/35077246</mixed-citation></ref><ref id="hanspub.37549-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Powles, T., Eder, J.P., Fine, G.D., et al. (2014) MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer. Nature, 515, 558-562. &lt;br&gt;https://doi.org/10.1038/nature13904</mixed-citation></ref><ref id="hanspub.37549-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Flies, D.B. and Chen, L. (2007) The New B7s: Playing A Pivotal Role in Tumor Immunity. Journal of Immunotherapy, 30, 251-260. &lt;br&gt;https://doi.org/10.1097/CJI.0b013e31802e085a</mixed-citation></ref><ref id="hanspub.37549-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L., Liu, X., Ren, X., et al. (2016) Smad2 and Smad3 Have Differential Sensitivity in Relaying TGFβ Signaling and Inversely Regulate Early Lineage Specification. Scientific Reports, 6, Article ID: 21602.  
&lt;br&gt;https://doi.org/10.1038/srep21602</mixed-citation></ref><ref id="hanspub.37549-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Sun, X., Cui, Y., Feng, H., Liu, H. and Liu, X. (2019) TGF-β Signaling Controls Foxp3 Methylation and T Reg Cell Differentiation by Modulating Uhrf1 Activity. Journal of Experimental Medicine, 216, 2819-2837.  
&lt;br&gt;https://doi.org/10.1084/jem.20190550</mixed-citation></ref><ref id="hanspub.37549-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Liu, M., Li, S. and Li, M.O. (2018) TGF-β Control of Adaptive Immune Tolerance: A Break from Treg Cells. BioEssays, 40, Article ID: 1800063. &lt;br&gt;https://doi.org/10.1002/bies.201800063</mixed-citation></ref><ref id="hanspub.37549-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Cohen, N., Mouly, E., Hamdi, H., et al. (2006) GILZ Expression in Human Dendritic Cells Redirects Their Maturation and Prevents Antigen-Specific T Lymphocyte Response. Blood, 107, 2037-2044. 
&lt;br&gt;https://doi.org/10.1182/blood-2005-07-2760</mixed-citation></ref><ref id="hanspub.37549-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Francisco, L.M., Salinas, V.H., Brown, K.E., et al. (2009) PD-L1 Regulates the Development, Maintenance, and Function of Induced Regulatory T Cells. Journal of Experimental Medicine, 206, 3015-3029.  
&lt;br&gt;https://doi.org/10.1084/jem.20090847</mixed-citation></ref></ref-list></back></article>